Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 13.95B USD.
Alto dividendo
La empresa es una gran pagadora de dividendos. Su ratio de pago de dividendos más reciente es del 32.56%.
Infravalorada
El PE más reciente de la empresa es 23.89, en un rango percentil bajo de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 88.74M acciones, lo que supone un aumento del 5.91% con respecto al trimestre anterior.
En posesión de Wallace Weitz
El inversor estrella Wallace Weitz posee 102.34K acciones de este valor.